Search result

10 Results found

	An open label extension study to characterise the long-term safety & efficacy of a factor VIII manufactured by the albumin free process in the treatment of previously treated patients with severe haemophilia A

	An open-label, single-arm, safety and efficacy study of recombinant human factor IX in children less than 6 years of age with severe haemophilia B

	Factor antihemofílico recombinante (rAHF-PFM) elaborado y formulado sin la adición de proteínas humanas ni animales: evaluación de una pauta profiláctica individualizada mediante parámetros farmacocinéticos en pacientes con hemofilia A previamente tratados. Recombinant antihemophilic factor (rAHF-PFM) manufactured without adding human or animal proteins: an assessment of an individualised prophylaxis based on pharmacokinetic parameters in patients with hemophilia A previously treated.

	Estudio de seguimiento de la eficacia y seguridad de Kogenate Bayer. Efficacy and safety of Kogenate Bayer: A follow-up study.

	ADVATE-PASS: seguimiento postautorización de seguridad de Advate rAHF-PFM en hemofilia A ADVATE-PASS: postmarketing safety follow-up of Advate rAHF-PFM in patients with hemophilia A

	Evaluación en doble ciego, aleatorizada y cruzada de la farmacocinética del Factor IX humano recombinante (BeneFIX) y de una nueva formulación de BeneFIX (rFIX-R), y evaluación abierta de la seguridad y la eficacia de rFIX-R en pacientes con hemofilia B de grado moderado a severo (FIX:C< o = 2%) tratados previamente. Double blind, randomized and cross-over evaluation of pharmacokinetics of recombinant human factor IX (BeneFIX) and of a new formulation of BeneFIX (rFIX-R), and open assessment of the safety and efficacy of rFIX-R in patients with haemophilia B moderate-severe (FIX:C < or = 2%) previously treated.

	Estudio abierto de la seguridad y la eficacia del factor IX recombinante humano (rFIX; Benefix) en pacientes tratados previamente (PTP) con hemofilia B (FIX:C < o = 2%). Open study of the safety and efficacy of recombinant human factor IX (rFIX; Benefix) in previously treated patients (PTP) with haemophilia B (FIX:C < or = 2%).

	Estudio abierto y de un solo brazo, de la seguridad y la eficacia del factor IX recombinante humano (rFIX; BeneFIX) en niños menores de 6 años de edad con hemofilia B severa. An open single-arm study of the safety and efficacy of recombinant human factor IX (rFIX; BeneFIX) in children younger than 6 with severe hemophilia B.

Results 8 of 10 found

1  2

Concept and coding by Valentina Rossi, Laboratory of Medical Informatics